04671oam 22010694 450 991079860100332120231227125414.01-5135-1299-41-5135-1605-1(CKB)3710000000736140(MiAaPQ)EBC4439543(Au-PeEL)EBL4439543(CaPaEBR)ebr11390987(CaONFJC)MIL901628(OCoLC)948782340(IMF)NRRAHFA(EXLCZ)99371000000073614020020129d2015 uf 0freurcnu||||||||rdacontentrdamediardacarrierAdministration des régimes fiscaux des industries extractives Manuel /Jack CalderWashington, D.C. :International Monetary Fund,2015.1 online resource (108 pages)1-5135-6789-6 Includes bibliographical references and index.L’administration des recettes fiscales tirées de ressources naturelles présente des difficultés particulières. Ce manuel est l’un des premiers ouvrages à s’intéresser de près à l’efficacité de l’administration des recettes issues des industries extractives. Il fournit aux décideurs politiques et aux agents des pays en développement et émergents des instructions pratiques pour mettre en place un cadre juridique, une organisation et des procédures solides pour gérer les recettes issues de ces industries. Il aborde le thème de la transparence et de sa promotion face une demande croissante des parties prenantes nationales et internationales pour plus de clarté et de responsabilité dans l’administration des recettes publiques tirées des ressources naturelles. Il approfondit également les solutions pour que les pays en développement parviennent à renforcer leurs capacités techniques et managériales pour mieux administrer ces recettes.BooksMineral industriesTaxationHandbooks, manuals, etcNatural resourcesTaxationHandbooks, manuals, etcRevenueAccountingHandbooks, manuals, etcPublic FinanceimfTaxationimfInternational TaxationimfNatural Resource ExtractionimfNatural ResourcesimfAgricultural and Natural Resource EconomicsimfEnvironmental and Ecological Economics: GeneralimfTaxation, Subsidies, and Revenue: GeneralimfBusiness Taxes and SubsidiesimfAuditingimfPublic AdministrationimfPublic Sector Accounting and AuditsimfEnvironmental managementimfPublic finance & taxationimfManagement accounting & bookkeepingimfExtractive industriesimfTaxation & duties lawimfNatural resourcesimfNatural resource taxesimfRevenue administrationimfTax administration core functionsimfTransfer pricing rulesimfRevenueimfTax administration and procedureimfUnited StatesimfMineral industriesTaxationNatural resourcesTaxationRevenueAccountingPublic FinanceTaxationInternational TaxationNatural Resource ExtractionNatural ResourcesAgricultural and Natural Resource EconomicsEnvironmental and Ecological Economics: GeneralTaxation, Subsidies, and Revenue: GeneralBusiness Taxes and SubsidiesAuditingPublic AdministrationPublic Sector Accounting and AuditsEnvironmental managementPublic finance & taxationManagement accounting & bookkeepingExtractive industriesTaxation & duties lawNatural resourcesNatural resource taxesRevenue administrationTax administration core functionsTransfer pricing rulesRevenueTax administration and procedure338.2Calder Jack1465288DcWaIMFBOOK9910798601003321Administration des régimes fiscaux des industries extractives3675226UNINA05234nam 2201249z- 450 991055748970332120220111(CKB)5400000000042934(oapen)https://directory.doabooks.org/handle/20.500.12854/77051(oapen)doab77051(oapen)77051(EXLCZ)99540000000004293420202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNon-small Cell Lung Cancer: Current Therapies and New Targeted TreatmentsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (258 p.)3-0365-0130-4 3-0365-0131-2 Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.Non-small Cell Lung CancerMedicinebicsscMedicine and Nursingbicsscadjuvant chemotherapybiomarkerchemotherapydaily practiceDNA polymerase betadocetaxelEGFR-TKIendocrine disordersepidermal growth factor receptorExpanded Access ProgramFDG-PETgenomic diagnosisglucose transporter 1HIP1Rimmune checkpoint inhibitorimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapyinterstitial lung diseaseKRASlung cancerlung neoplasmsmeta-analysismetastasismethylationmultiple cancersmutationnetwork meta-analysisnivolumabnon-small cell lung cancernon-small-cell lung cancernonsmall cell lung cancerNSCLCnucleotide-diphosphate kinaseoligometastasisosimertinibPD-1PD-1 blockadePD-1 inhibitorsPD-L1PD-L1 expressionPD-L1 inhibitorsphase I/II trialplatinum-based first-linepredictive biomarkerpreviously treated patientsprognosisprognostic factorprognostic factorspulmonary fibrosispulmonary pleomorphic carcinomaRAD51B methylationradiology and other imagingreal-world datarechallengerecurrenceresponsivenessretrospective analysisRUNX1S-1salvage surgerysequencingstage IIIA-N2surgerysurvivalT790Mtargeted therapyTP53 mutationstumor-bearing patientstyrosine kinase inhibitorsunresectableβ-cateninMedicineMedicine and NursingUchino Junjiedt1302981Uchino JunjiothBOOK9910557489703321Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments3026799UNINA